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Introduction
Dizziness may be caused by many disturbances in central 
and peripheral neural function. Vertigo, dizziness, and dis-
equilibrium consistently rank among the most common com-
plaints experienced by individuals with vestibular dysfunc-
tion. Moreover, vestibular deficits appear to be among the most 
common causes of dysequilibrium symptoms requiring medi-
cal intervention. Decreased function of the peripheral vestibu-
lar system can result in decreased visual acuity during head 
movements and a degradation of postural control. The man-
agement of dizziness related symptoms has mostly involved 
the use of pharmacological agents during the early acute 
phase of symptom onset. The common objective of drug treat-
ment is to suppress vestibular sensory input. This is thought to 
reduce conflicting sensory input, control undesirable percep-
tions, and improve the quality of life of patients.
Vestibular signals originate from the sensory organs of the 
three semicircular canals and two macular organs within the 
petrous portion of the temporal bone (Fig. 1). The vestibular 
neuroepithelium including hair cells, supporting cells as wells 
as afferent and efferent neurons are thought to interact with a 
diverse number of neuroactive substances (neurotransmitters 
and neuromodulators), which bind to specific receptors at the 
postsynaptic membrane. During normal chemical synaptic 
transmission, these neurotransmitters and modulators are syn-
thesized and stored in presynaptic vesicles and are released into 
the synapse to bind and act on postsynaptic cell receptors dur-
ing the transmission and processing of sensory information. 
Glutamate [Glu or a glutamate-like excitatory amino acid 
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The use of pharmacological agents is often the preferred approach to the management of 
vestibular dysfunction. In the vestibular sensory pathways, the sensory neuroepithelia are 
thought to be influenced by a diverse number of neuroactive substances that may act to 
enhance or inhibit the effect of the primary neurotransmitters [i.e., glutamate (Glu) and ace-
tylcholine (ACh)] or alter their patterns of release. This review summarizes various efforts to 
identify drug targets including neurotransmitter and neuromodulator receptors in the vestib-
ular sensory pathways. Identifying these receptor targets provides a strategic basis to use 
specific pharmacological tools to modify receptor function in the treatment and manage-
ment of debilitating balance disorders. A review of the literature reveals that most investiga-
tions of the neuropharmacology of peripheral vestibular function have been performed us-
ing in vitro or ex vivo animal preparations rather than studying drug action on the normal 
intact vestibular system in situ. Such noninvasive approaches could aid the development of 
more accurate and effective intervention strategies for the treatment of dizziness and verti-
go. The current review explores the major neuropharmacological targets for drug action in 
the vestibular system. J Audiol Otol 2017;21(3):125-132
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(EAA)] and acetylcholine (ACh) are widely accepted as be-
ing the primary neurotransmitters released by vestibular hair 
cells and efferent neural terminals respectively [1,2]. In the 
peripheral vestibular system, there are a variety of other neu-
roactive molecules that are thought to be present and may act 
as modulators at these synapses including γ-amino butyric 
acid (GABA), substance P, calcitonin gene-related protein 
(CGRP), and opioid peptides. These neuromodulators may 
affect the response of neurons by facilitating or inhibiting the 
effect of the primary neurotransmitters or by altering patterns 
of release. Neuroactive substances bind with numerous cor-
responding postsynaptic and presynaptic receptors to medi-
ate neural transmission or modulate the response of postsyn-
aptic neurons. Pharmacologic agents can act at these receptors 
to alter synaptic messaging. In this way, pharmacological 
agents have a diverse array of cellular targets that provide a 
means for modifying sensory transmission. In Fig. 2, many of 
the possible targets of pharmacological agents in the periph-
eral vestibular sensory neuroepithelium are summarized. 
Neuroactive Substances and 
Receptors
Molecular biological, biochemical, and electrophysiologi-
cal evidences suggest that glutamate, ACh, histamine, en-
kephalins, GABA, CGRP, and substance P are all released to 
some extent as neurotransmitters or modulators in the periph-
eral vestibular system [3,4]. In central vestibular circuits, the 
vestibular nuclei integrate vestibular, somatosensory, pro-
prioceptive, and visual inputs. These diverse synaptic inputs 
to the nuclei are also represented by glutamatergic, GABAer-
gic, histaminergic, serotoninergic, and dopaminergic neurons 
[4]. These neural projections to vestibular nuclei arise mainly 
from vestibular afferent neurons, spinal afferents, cerebellum, 
and more rostral descending visual and motor control systems 
[5]. The following provides an overview of neurotransmitter 
and neuromodulator receptors identified in the peripheral ves-
tibular neuroepithelium and ganglion as well as in central ves-
tibular nuclei.
Glutamate receptors
In the vestibular system, glutamate is an EAA and the ma-
jor neurotransmitter of the vestibular sensory hair cells [1]. 
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Fig. 1. Schematic illustration of the 
vestibular end organ (top), which 
includes the neuroepithelium of the 
crista ampullaris (lower left) and 
vestibular macula (lower right). The 
membranous labyrinth is fluid-filled 
with endolymph (blue color on top 
panel) and perilymph (red color). The 
vestibular system is composed of 
five organs; three semicircular canals 
also called “crista sensors” to detect 
angular accelerations of the head 
and two otolith organs also called 
“macular sensors” to detect the lin-
ear acceleration of the head. In the 
crista, kinocilia and stereociliary bun-
dles of hair cells extend into the ge-
latinous cupula. During angular ac-
celeration of the head, surrounding 
endolymph lags and moves in the 
opposite direction in response to ro-
tational acceleration. In the macula, 
dense calcium carbonate (called 
“otoconia”) are embedded within the 
otoconial layer, which is greater den-
sity than surrounding fluid and tis-
sues of the maculae. During linear 
acceleration of the head, high densi-
ty of otoconial layer causes the oto-
conial layer to shift position relative 
to the neuroepithelium producing a 
movement of stereociliary bundles 
of receptor hair cells.
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Glutamate interacts with ionotropic receptors such as α-amino-
3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), N-
methyl-D-aspartic acid (NMDA), and kainic acid (KA) as well 
as metabotropic receptors such as metabotropic glutamate re-
ceptor 1-8 (mGluR1-8) [1,6]. Ionotropic and metabotropic 
glutamate receptors are located on the vestibular primary af-
ferent dendrites. These receptors mediate the input signals 
from vestibular hair cells and also between primary afferents 
and second order vestibular nuclei neurons (see below).
AMPA is a major glutamate receptor in the inner ear. The 
AMPA response to glutamate produces a postsynaptic in-
crease in intracellular cations including especially Na+ post-
synaptically; these cations thus play a functional role in AM-
PA-mediated depolarization of vestibular afferent neurons [7]. 
Immunohistochemical studies have suggested that AMPA re-
ceptor subunits GluR1, GluR2-3, and GluR4 are expressed 
in mammalian vestibular hair cells and calyx afferents [3,7]. 
The application of a specific AMPA/KA antagonist (1.5 mM 
DNQX) to the mouse vestibular afferents blocked AMPA re-
sponses [7]. The neurons of the vestibular nuclei also express 
AMPA EAA receptors. Popper, et al. [8] used immunohisto-
chemistry in the vestibular nuclei of the chinchilla and found 
ionotropic AMPA receptor subunits (GluR2-3) in the most neu-
rons, (GluR1) in some neurons, and (GluR4) in the fewest num-
ber of neurons. 
There is evidence in support of the presence of the NMDA 
receptors on both vestibular hair cells and afferent neurons. 
The NMDA receptor (NMDAR) subunits NMDAR1, NMDA-
R2A, NMDAR2B, NMDAR2C, and NMDAR2D are report-
edly expressed in rat vestibular afferent neurons [6]. Electro-
physiological studies have suggested that the application of 
NMDA antagonists [2-amino-5-phosphonopentanoic acid 
(AP5) and 7-chloro-kynurenic acid (7ClKyn)] decreased spon-
taneous spike discharge in vestibular afferents [9]. In addition, 
an electrophysiological study using whole-cell patch clamp 
methods in the brainstem reported NMDA receptors contrib-
ute to afferent synaptic transmission in the medial vestibular 
nucleus (MVN) of the rat [10]. These studies suggest that 
NMDA receptors contribute to afferent neurotransmission in 
both the peripheral and central vestibular system.
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Fig. 2. Schematic illustration of type I (left) and type II (right) hair cell are shown with primary afferent and efferent neurons. Calyx or di-
morphic afferents (gray fibers) envelop most of the basolateral surface of the type I hair cell and bouton and/or dimorphic afferents in-
nervate the type II hair cell (gray fibers). Efferent axons arising from the brainstem contact the external surface of calyx afferent and 
make direct contact with the basolateral surfaces of type II hair cell (green fiber). Synaptic vesicles are tethered to the synaptic ribbons 
and release glutamate to trigger action potentials in primary afferent neurons. Efferent neurons modulate afferent neural responses. 
Possible targets of pharmacological agents include AMPA, NMDA, KA, H3-4, GABAA-B, μ-opioid, D1-2, nACh, mACh, CGRP, enkepha-
lin, and substance P receptors in the postsynaptic membranes of vestibular afferent fibers. AMPA: α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid, NMDA: N-methyl-D-aspartic acid, KA: kainic acid, H3-4: histamine 3-4, GABAA-B: γ-amino butyric acidA-B, D1-
2: dopamine 1-2, nACh: nicotinic acetylcholine, mACh: muscarinic acetylcholine, CGRP: calcitonin gene-related protein.
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Evidence for KA glutamate-receptors in the vestibular sys-
tem is far less compelling, and glutamate affinity at ionotropic 
KA receptors seems to be low. There are five KA receptor sub-
units (GluR5-7 and KA1-2); however, GluR5, GluR6, KA1, 
and KA2 were only immunochemically expressed in mam-
malian vestibular ganglia [6]. Several pharmacological stud-
ies have suggested that KA receptors like other glutamate re-
ceptors act during afferent neurotransmission in mammalian 
vestibular neurons. Trimetazidine, a potent antagonist of KA 
receptor, blocked kainate-induced excitatory responses in the 
rat vestibular afferent neurons [11]. AMPA/KA receptor an-
tagonists, CNQX and NBQX, were delivered to the intersti-
tial fluids of the inner ear through perilymphatic perfusion 
and the effect on vestibular compound action potentials using 
linear vestibular sensory evoked potentials (VsEPs) showed 
VsEP response amplitudes were significantly reduced [12]. 
Evidence for metabotropic glutamate receptors in the vestib-
ular pathways is far less compelling, with a limited number of 
studies. Numerous studies have shown that the afferents inner-
vating vestibular hair cells are triggered by responses to the 
activation of glutamate receptors, and glutamate is a major af-
ferent neurotransmitter at both peripheral and central afferent 
synapses.
ACh receptors
The primary neurotransmitter of vestibular efferent synaps-
es is acetylcholine [13,14]. In mammals including humans, 
the activity of choline acetyltransferase (ChAT), which syn-
thesizes ACh, and acetylcholinesterase (AChE), which inac-
tivates ACh, was found in numerous bouton terminals at the 
basal surface of the vestibular hair cells [13,15]. Two major 
classes of ACh receptors found in the vestibular neuroepithe-
lium are nicotinic ACh receptor (nAChR) and muscarinic 
ACh receptor (mAChR). Over the last decade, Holt and his 
colleagues have focused on addressing the function of the 
vestibular efferent system and reported that vestibular effer-
ent neurons produce both excitation and inhibition of vestib-
ular responses in animals [13,14,16]. Their findings indicate 
that efferent-mediated inhibition results from the activation 
of α9α10 nACh receptors on type II vestibular hair cells and 
direct efferent-mediated excitation of vestibular afferents is 
mediated by mACh (mAChR1, 3, 5) and/or nACh receptors 
(α4, α6, and β2) [14]. 
nACh receptors are ionotropic receptors (i.e., ligand-gated 
ion channels) composed of diverse subunits: α3, α5-7, α9α10, 
and β2-4 in the vestibular end organs as well as α2-7 and 
β2-4 in the vestibular afferent neurons [13,14]. Based on their 
inherent signaling mechanisms, nAChR-mediated responses 
are faster than mAChR-mediated responses. Most nAChRs 
control the membrane permeability to cations especially Ca2+ 
ions [17] and when activted lead to membrane depolarization 
and excitation of vestibular afferents. However, α9α10 nACh 
receptors when activated increase Ca2+ entry into the cell, which 
in turn activates Ca2+-dependent K+ (SK) channels. This pro-
duces membrane hyperpolarization, inhibition of neurotrans-
mitter release and a reduction in the excitatory drive on prima-
ry afferents [14].
In addition to nACh receptors, mACh receptors are metabo-
tropic receptors (i.e., G-protein-coupled receptors) and its re-
ceptor subunits (m1-5) are expressed in mammalian vestibu-
lar end organs and Scarpa’s ganglion [13,18]. Because of the 
G-protein-coupled receptor signaling mechanism, mAChR-
mediated responses should follow relatively slower kinetics 
than nAChRs. Despite the slow kinetics, mACh receptors have 
been the target of vestibular suppressants (e.g., scopolamine). 
Whole-cell patch clamp recordings of rat vestibular afferent 
neurons showed that the mAChR agonist, oxotremorine-M, 
significantly reduced outward polarizing K+ current called 
“M-current,” causing depolarization and excitation of the neu-
rons [19]. Its action was blocked by atropine, an mAChR an-
tagonist, thus suggesting the presence of mAChRs on vestibular 
afferent neurons. Recently using in vivo recordings, pharmaco-
logical reduction of M-current was shown to significantly al-
ter peripheral vestibular afferent responses suggesting that ef-
ferent control of mAChRs may provide a means to modulate 
primary afferent response characteristics [20].
In the vestibular nuclei, specific nAChR and mAChR sub-
units were not clearly identified. Even in the vestibular effer-
ent neurons of brainstem, ChAT (responsible for the synthe-
sis of ACh) is found only in some of the vestibular efferent 
neurons [13] suggesting that some of these neurons may not 
be mediated by nAChR and mAChR. Intracellular record-
ings of rat MVN have shown that nACh and mACh receptor 
agonists produced membrane depolarization [21]. Extracellu-
lar recordings in all four major vestibular nuclei (i.e., medial, 
lateral, inferior, and superior) of the rat vestibular nuclear 
complex have indicated that nACh and mACh receptor ago-
nists (carbachol and muscarine) increased spontaneous firing 
rates and established that the effect of ACh agonists was high-
est in the MVN [22]. These studies indicate that both nACh 
and mACh receptors are present and influence the excitability 
of the mammalian vestibular nucleus neurons.
GABA receptors
The role of GABA in the vestibular system has been widely 
debated, but a clear consensus has not been reached. GABA 
receptors are divided into three types [23]: 1) GABAA recep-
tor is an ionotropic receptor controlling a ligand-gated Cl- 
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ion channel, 2) GABAB receptor is a metabotropic receptor 
which interacts with Gi to inhibit adenylyl cyclase, upregulates 
K+ channels, and downregulates Ca2+ channels, and 3) GABAC 
receptor is a transmitter-gated Cl- channel but is not likely ex-
pressed in the vestibular system. Meza [24] and her research 
group completed a considerable amount of work studying 
mechanisms of GABA and its receptors in the vestibular sen-
sory neuroepithelium. GABA synthesizing enzymes, L-gluta-
mate decarboxylase (GAD) and GABA transaminase (GA-
BA-T) are present as well as GABAA receptor-subunits γ1, γ2, 
and γ3 are expressed in mammalian vestibular hair cells and 
Scarpas’s ganglion [24]. These early findings were interpreted 
as indicating that GABA may function as an afferent neu-
rotransmitter in vestibular hair cells. However, this hypothesis 
has not received convincing support. The presence of GABA 
in vestibular epithelia is highly variable across species espe-
cially within hair cells. GABA-like immunoreactivity in effer-
ent endings of the mammal was reported in the squirrel mon-
key but not rat or guinea pig and in the bird GABA labeling 
was reported for the pigeon with weak labeling in the chicken 
[25]. Electrophysiological studies also showed that the appli-
cation of GABA agonists and antagonists had no direct effect 
on the vestibular afferents [26]. These investigators plausibly 
argued that GABA is not the neurotransmitter in the afferent 
synapse, but may be a facilitator of glutamate release. 
Rather than being a primary afferent transmitter, GABA 
may have a modulatory role being co-released by efferent neu-
rons and serve to modulate afferent activity in both the ves-
tibular and auditory systems rather than act as the principal 
hair cell transmitter driving sensory discharge patterns [13]. 
The mechanism of GABA action remains unclear, but it seems 
to be involved to some extent in modulating Ca2+ signalling 
mediated by inhibition of Ca2+ channels presynaptically and/
or activation of Cl- channels. Thus, it may indirectly reduce 
neurotransmitter release presynaptically to disfacilitate post-
synaptic cells [13,26].
Central vestibular nuclei are known to receive potent in-
hibitory inputs mediated by GABAA and GABAB receptors. 
These GABAergic inputs arise primarily from commissural fi-
bers of vestibular nuclei and cerebellum [5]. GABAA receptor 
agonists including diazepam, lorazepam and clonazepam as 
well as GABAB receptor agonists, baclofen, are the most wide-
ly used benzodiazepines and these act in the central vestibular 
sensory pathways [27,28].
Histamine receptors
Histamine and its four receptors (H1, H2, H3, and H4) have 
been identified in the vestibular sensory pathway: H1, H2, 
and H3 receptors in the vestibular hair cells [29]; H3 and H4 
receptors in the vestibular afferents [30,31]. All histamine re-
ceptors are metabotropic, with four different G-protein coupled 
receptors acting through a second messenger intracellularly. 
Evidence for histamine receptors in the vestibular system sug-
gests that they may perform an important role in the control of 
vestibular function.
Even though H1-3 receptors are expressed and their acti-
vation induces an influx of Ca2+ in vestibular hair cells, intra-
cellular recordings of guinea pig vestibular hair cells have 
shown that H3 receptors may mediate a notably larger in-
crease in Ca2+ permeability (larger influx of Ca2+) compared to 
H1 and H2 receptors [29]. Recently, H4 antagonist JNJ7777120 
has been studied in Scarpa’s ganglion of the rat and electro-
physiological recordings showed reversible inhibitory effects 
elicited by the H4 receptor antagonist without subsequent ex-
citatory action [31]. However, this effect may not be shared 
by central vestibular nucleus neurons. The findings suggest 
that H4 receptors mediate an excitatory action in vestibular 
primary afferent neurons. Histamine also modulates the neu-
ral activities of the second order neurons in the vestibular nu-
clei and its various effects on the vestibular nuclei have been 
reported in several electrophysiological studies. Dimaprit, a 
selective H2 receptor agonist, produced an excitatory action 
on rat MVN neurons, and its effect was blocked by ranitidine, 
a selective H2 receptor antagonist, blocked its effect [32]. Be-
tahistine (strong H3 receptor antagonist and weak H1 recep-
tor agonist), produced a weak excitatory action, but signifi-
cantly reduced the excitatory effect elicited by histamine on 
the MVN neurons [32,33]. Thus, the effectiveness of hista-
mine receptor antagonists on motion sickness, vertigo and diz-
ziness can be explained by their action in reducing the excit-
atory actions in the mammalian vestibular nuclei and/or in the 
vestibular periphery.
Opioid peptide receptors
The opioid receptors preferentially activated by the enkeph-
alins largely comprise three receptor subtypes (μ-, k-, and 
δ-receptors; G-protein coupled receptors) based on their phar-
macological characteristics [34]. In addition to three major 
receptor subtypes, the opioid-like orphan (ORL1) receptor is 
another member of the opioid receptor family and is specifi-
cally activated by nociceptin. Enkephalins and opioid recep-
tors were found in the vestibular sensory pathway: μ- and k-
opioid receptors in the vestibular hair cells and afferent neurons; 
δ-opioid and ORL1 receptors in the MVN neurons [4,13,35]. 
Opioid peptides may be candidates for modulating synaptic 
transmission in the vestibular afferent neurons. Whole-cell 
patch clamp recordings of amphibian vestibular hair cells 
showed that vestibular afferents were excited by μ-receptor 
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agonists at the postsynaptic level (postsynaptic activation of 
afferent neurons) and inhibited by k-receptor agonists at the 
presynaptic level (inhibition of hair cells), reducing Ca2+ cur-
rents in the hair cells [36]. This study suggests that the ves-
tibular afferents are regulated by the complex of opioid re-
ceptors. Electrophysiological data from mammalian MVN 
neurons indicated that the δ-opioid receptor agonists inhibit-
ed rotation- and glutamate-induced firing rates [37] and ORL1 
receptor agonists also inhibited the spontaneous discharge 
rates [35]. These results suggest that enkephalins modulate 
afferent transmission at both the peripheral and the central 
vestibular levels.
Dopamine receptors
Dopamine receptors have been divided into two families: 
a D1-like family of dopamine receptors including D1 and D5 
as well as a D2-like family including D2, D3, and D4 (all G-
protein coupled receptors) [38]. Several findings support a 
possible involvement of dopamine as a modulator of excitato-
ry neurotransmission at postsynaptic afferent terminals [38,39]. 
In the mammalian vestibular neuroepithelium, immunochem-
ical evidence has indicated that dopamine D1 and D2 receptors 
are expressed in both type I and type II vestibular hair cell 
membranes [40]. Pharmacological studies using extracellular 
recordings showed that frog vestibular afferents were excited 
by EAA agonists and the excitation was suppressed by co-ad-
ministration of D1 or D2 agonists [39]. This result suggests 
that the responses of D1 and D2 receptors act not only to 
modulate glutamate receptors postsynaptically, but also may 
have a protective function in the vestibular dendrites. In the 
vestibular nuclei, guinea-pig MVN neurons were depolarized 
only by D2 agonists; D1 receptors were not involved, sug-
gesting the presence of D2 receptors in the mammalian MVN 
[41]. In clinical applications, dopaminergic receptor antago-
nists such as prochlorperazine, promethazine, and domperi-
done [27] might exert a modulatory action on vestibular affer-
ent neurons. 
CGRP receptors
Immunochemical studies found that ChAT and CGRP prob-
ably co-exist in vestibular efferent neurons [13,42]. Electro-
physiological data confirmed the function of CGRP receptor 
and showed that CGRP released from efferent neurons in-
creased vestibular afferent activities [3]. Sewell and Starr [43] 
argued that CGRP released from efferent neurons produces 
an increase in spontaneous discharge rate and this increases 
the probability of excitatory postsynaptic potentials. Recently, 
mice with loss of αCGRP gene (-/-) showed a significant re-
duction in Vestibular Ocular Reflex (VOR) gain, suggesting 
CGRP dependent effects in peripheral and/or central vestibu-
lar pathways [42]. Taken together, the results of these studies 
regarding CGRP suggest that efferent fibers making contact 
with both calyx afferents and type II hair cells contain CGRP 
and CGRP may exert modulatory effects on ACh receptors to 
increase the excitability of peripheral vestibular afferents. 
Immunocytochemistry studies have reported the presence 
of substance P in mammalian vestibular hair cells and Scar-
pa’s ganglion [3,4,44] and investigated the coexistence of sub-
stance P and CGRP in the rat vestibular end organs using im-
munocytochemistry. Usami, et al. [44] revealed three different 
types of immunoreactivities localized within as well as be-
neath the sensory epithelia in rats. Since most immunoreactiv-
ity data clearly indicate that CGRP is associated with efferent 
fibers, the finding of substance P also supports the coexistence of 
the two and suggests a possible role for substance P in modu-
lating the peripheral vestibular system.
Conclusion
The current review of the literature reveals that basic re-
search on the pharmacological targets of drugs and medica-
tions has provided many answers to questions about the bio-
chemical, molecular and functional nature of neural signaling 
in the vestibular sensory pathways. If we are to understand 
the action of drugs and medications, we must first under-
stand the target receptors through which drugs and medica-
tions act to produce clinical outcomes. A considerable amount 
of effort has been carried out to identify neurotransmitters 
and modulators in the vestibular system using in vitro animal 
preparations. Medications work by mimicking, suppressing 
or otherwise altering these normal signaling processes. One 
may speculate and infer that the lessons learned from study 
of target processes and mechanisms, although often discov-
ered in vitro, also apply to drug actions in the intact animal. 
However, in many cases particularly in the case of new and 
promising medications, drug actions in the intact animal are 
not fully understood. Therefore, developing reliable direct in 
vivo assessment tools for the study of vestibular sensory path-
ways will be important to accurately quantify drug effects on 
vestibular function. Clinically, in vivo research on vestibular 
pharmacological targets may aid the development of more ac-
curate and effective intervention strategies for the treatment 
of dizziness and vertigo.
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